SynthesisPloS one2010
Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials.
Synthesis in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 15 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 15 syntheses or guidelines pooled it.
- Progress in Pathological and Therapeutic Research of HIV-Related Neuropathic Pain.Cellular and molecular neurobiology · 2023Pooled it
- HIV Neuropathy-a Review of Mechanisms, Diagnosis, and Treatment of Pain.Current pain and headache reports · 2021Pooled it
- Pharmacologic and Non-Pharmacologic Interventions for HIV-Neuropathy Pain. A Systematic Review and a Meta-Analysis.Medicina (Kaunas, Lithuania) · 2019Pooled it
- Effects of cannabinoid administration for pain: A meta-analysis and meta-regression.Experimental and clinical psychopharmacology · 2019Pooled it
- Pooled it
- 2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Guideline
- Gabapentin for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Topical capsaicin (high concentration) for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Natural products and complementary therapies for chemotherapy-induced peripheral neuropathy: A systematic review.Critical reviews in oncology/hematology · 2016Pooled it
- Inhaled Cannabis for Chronic Neuropathic Pain: A Meta-analysis of Individual Patient Data.The journal of pain · 2015Pooled it
- Pooled it
- Gabapentin for chronic neuropathic pain and fibromyalgia in adults.The Cochrane database of systematic reviews · 2014Pooled it
- Lamotrigine for chronic neuropathic pain and fibromyalgia in adults.The Cochrane database of systematic reviews · 2013Pooled it
- Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews.The Cochrane database of systematic reviews · 2013Pooled it
- Topical capsaicin (low concentration) for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2012Pooled it
- Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial.Journal of diabetes investigation · 2016Trial
- Randomized, Double-Blind, Crossover Trial of Amitriptyline for Analgesia in Painful HIV-Associated Sensory Neuropathy.PloS one · 2015Trial
- Experience and challenges presented by a multicenter crossover study of combination analgesic therapy for the treatment of painful HIV-associated polyneuropathies.Pain medicine (Malden, Mass.) · 2013Trial
- Guideline of the German Society of Neurology (DGN): "diagnosis and therapy of HIV-1-associated neurological disorders".Neurological research and practice · 2026Review
- Sex differences in the capacity of minor phytocannabinoids to attenuate nociceptive insults in HIV-1 Tat-expressing mice.NeuroImmune pharmacology and therapeutics · 2025Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSignificant pain from HIV-associated sensory neuropathy (HIV-SN) affects ∼40% of HIV infected individuals treated with antiretroviral therapy (ART). The prevalence of HIV-SN has increased despite the more widespread use of ART. With the global HIV prevalence estimated at 33 million, and with infected individuals gaining increased access to ART, painful HIV-SN represents a large and expanding world health problem. There is an urgent need to develop effective pain management strategies for this condition. METHOD AND
findings
objectiveTo evaluate the clinical effectiveness of analgesics in treating painful HIV-SN.
designSystematic review and meta-analysis. DATA SOURCES: Medline, Cochrane central register of controlled trials, www.clinicaltrials.gov, www.controlled-trials.com and the reference lists of retrieved articles. SELECTION CRITERIA: Prospective, double-blinded, randomised controlled trials (RCTs) investigating the pharmacological treatment of painful HIV-SN with sufficient quality assessed using a modified Jadad scoring method. REVIEW
methodsFour authors assessed the eligibility of articles for inclusion. Agreement of inclusion was reached by consensus and arbitration. Two authors conducted data extraction and analysis. Dichotomous outcome measures (≥ 30% and ≥ 50% pain reduction) were sought from RCTs reporting interventions with statistically significant efficacies greater than placebo. These data were used to calculate RR and NNT values.
resultsOf 44 studies identified, 19 were RCTs. Of these, 14 fulfilled the inclusion criteria. Interventions demonstrating greater efficacy than placebo were smoked cannabis NNT 3.38 95%CI(1.38 to 4.10), topical capsaicin 8%, and recombinant human nerve growth factor (rhNGF). No superiority over placebo was reported in RCTs that examined amitriptyline (100mg/day), gabapentin (2.4 g/day), pregabalin (1200 mg/day), prosaptide (16 mg/day), peptide-T (6 mg/day), acetyl-L-carnitine (1g/day), mexilitine (600 mg/day), lamotrigine (600 mg/day) and topical capsaicin (0.075% q.d.s.).
conclusionsEvidence of efficacy exists only for capsaicin 8%, smoked cannabis and rhNGF. However,rhNGF is clinically unavailable and smoked cannabis cannot be recommended as routine therapy. Evaluation of novel management strategies for painful HIV-SN is urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.